Skip to main
MGNX
MGNX logo

MacroGenics (MGNX) Stock Forecast & Price Target

MacroGenics (MGNX) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 40%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Macrogenics Inc has established a strong foundation for growth through its advanced antibody engineering capabilities and a diverse pipeline of product candidates aimed at critical therapeutic areas, particularly in oncology. The company is poised for increased momentum, with the anticipation of a greater flow of clinical trial data from its variety of earlier-stage programs, highlighting its commitment to innovation and strategic importance within the pharmaceutical landscape. Moreover, the initiation of patient dosing in pivotal clinical trials, such as the P2 LINNET trial for lorigerlimab, presents additional opportunities for partnership and capital generation, further enhancing the company’s financial outlook.

Bears say

Macrogenics Inc reported a disappointing financial performance, with a GAAP net loss of $41 million, significantly surpassing both company and consensus estimates of $(0.39) and $(0.73) per share, respectively. The company's lower-than-expected revenue of $13 million and a 23% year-over-year decrease in research and development spending indicate challenges in advancing its clinical pipeline of antibody-based therapeutics. Additionally, while operating expenses decreased by 19% year-over-year, the persistent and widening net losses highlight ongoing financial vulnerabilities that undermine confidence in the company's future profitability prospects.

MacroGenics (MGNX) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 40% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MacroGenics (MGNX) Forecast

Analysts have given MacroGenics (MGNX) a Hold based on their latest research and market trends.

According to 5 analysts, MacroGenics (MGNX) has a Hold consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MacroGenics (MGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.